

This communication should be viewed by:

Primary Care Providers Behavioral Health Providers Clinical staff

## Pharmaceutical Policy Updates Effective August 1, 2024

To view all current MVP Health Care<sup>®</sup> (MVP) Pharmaceutical policies, *Sign In* at **mvphealthcare.com/providers** and select *Resources*, then *Medical Policies* then *Pharmaceutical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their statuses. Policies fall into one of the following categories:

- New Denotes a new policy
- **Updated** Updated policies have content changes that may affect coverage criteria for services and/or drugs
- Reviewed/No Changes Policies that have been reviewed but have no content change
- **Archived** Denotes a policy that is no longer active

The following policies are effective August 1, 2024, and will be available for viewing on or before July 1, 2024. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Vascular Endothelial Growth Factor Inhibitors	Updated
Vascular Endothelial Growth Factor Inhibitors Part B	Updated
Copayment Adjustment for Medical Necessity	Reviewed/No Changes
Medicare Part B vs Part D Determination	Reviewed/No Changes
Effective June 1, 2024	
Casgevy	New policy
Casgevy Part B	New policy
Lenmeldy	New policy
Lenmeldy Part B	New policy
Lyfgenia	New policy
Lyfgenia Part B	New policy
Pulmonary Hypertension Advanced Agents Commercial	New policy
Amtagvi	New policy
Amtagvi Part B	New policy
Select Injectables for Asthma	Updated
Select Injectables for Asthma Part B	Updated

